Pharvaris delivered Q2 2025 results with increased investment in R&D as multiple Phase 3 trials advanced. Despite a growing net loss, the company remains well-funded, especially after a public offering completed in July, which extended its cash runway into 1H 2027.

Pharvaris ended Q4 2024 with a net loss of €34.8M and zero revenue, reflecting ongoing investment in clinical trials. The company maintained a strong liquidity position with €281M in cash and cash equivalents.